103 related articles for article (PubMed ID: 30711952)
21. Tricine co-ligand improved the efficacy of
Shaghaghi Z; Abedi SM; Hosseinimehr SJ
Biomed Pharmacother; 2018 Aug; 104():325-331. PubMed ID: 29775901
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of single amino acid chelate derivatives and regioselective radiolabelling of a cyclic peptide for the urokinase plasminogen activator receptor.
Armstrong AF; Lemon JA; Czorny SK; Singh G; Valliant JF
Nucl Med Biol; 2009 Nov; 36(8):907-17. PubMed ID: 19875047
[TBL] [Abstract][Full Text] [Related]
23. Miniaturized Radiochemical Purity Testing for
Fuente A; Zanca R; Boni R; Cataldi AG; Sollini M; Lazzeri E; Mariani G; Erba PA
J Nucl Med Technol; 2017 Sep; 45(3):236-240. PubMed ID: 28705928
[TBL] [Abstract][Full Text] [Related]
24. Comparative evaluation of glutamate-sensitive radiopharmaceuticals: Technetium-99m-glutamic acid and technetium-99m-diethylenetriaminepentaacetic acid-bis(glutamate) conjugate for tumor imaging.
Kakkar D; Tiwari AK; Chuttani K; Kaul A; Singh H; Mishra AK
Cancer Biother Radiopharm; 2010 Dec; 25(6):645-55. PubMed ID: 21204758
[TBL] [Abstract][Full Text] [Related]
25. Labelling of the anti-III-neurotubulin monoclonal antibody by 99mTc and its binding to responsible antigen.
Slapnicková K; Kolárová P; Kynclová K
Nucl Med Rev Cent East Eur; 2007; 10(1):1-5. PubMed ID: 17694493
[TBL] [Abstract][Full Text] [Related]
26. Kit for preparation of multimeric receptor-specific ⁹⁹mTc-radiopharmaceuticals based on gold nanoparticles.
Ocampo-García B; Ferro-Flores G; Morales-Avila E; Ramírez Fde M
Nucl Med Commun; 2011 Nov; 32(11):1095-104. PubMed ID: 21860334
[TBL] [Abstract][Full Text] [Related]
27. [Biodistribution of (99m)Tc-labeled anti-VEGF mAb 5-FU loaded polylactic acid nanoparticles in human gastric carcinoma xenografts].
Huang KH; Liu JH; Zhu ZH; Li XX; Lu XP; Zhou SY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1137-40. PubMed ID: 17715009
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, characterization and bioevaluation of technetium-99m labeled N-(2-Hydroxybenzyl)-2-amino-2-deoxy-D-glucose as a tumor imaging agent.
Nadeem Q; Khan I; Javed M; Mahmood Z; Dar UK; Ali M; Hyder SW; Murad S
Pak J Pharm Sci; 2013 Mar; 26(2):353-7. PubMed ID: 23455207
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of analogues of HYNIC as bifunctional chelators for technetium.
Meszaros LK; Dose A; Biagini SC; Blower PJ
Dalton Trans; 2011 Jun; 40(23):6260-7. PubMed ID: 21350776
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of diethylenetriamine pentaacetic acid-polyethylene glycol-folate: a new folate-derived, (99m)Tc-based radiopharmaceutical.
Liu M; Xu W; Xu LJ; Zhong GR; Chen SL; Lu WY
Bioconjug Chem; 2005; 16(5):1126-32. PubMed ID: 16173789
[TBL] [Abstract][Full Text] [Related]
31. Radiolabeled L-lysine for tumor imaging.
Karacalioglu AO; Yang DJ; Azhdarinia A; Mendez R; Oh C; Kohanim S; Chanda M; Greenwell AC; Yu DF; Kim EE
Acad Radiol; 2006 Nov; 13(11):1327-37. PubMed ID: 17070450
[TBL] [Abstract][Full Text] [Related]
32. Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling.
Fleetwood F; Güler R; Gordon E; Ståhl S; Claesson-Welsh L; Löfblom J
Cell Mol Life Sci; 2016 Apr; 73(8):1671-83. PubMed ID: 26552422
[TBL] [Abstract][Full Text] [Related]
33. Organometallic 99mTc(III) '4 + 1' bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies.
Kunstler JU; Veerendra B; Figueroa SD; Sieckman GL; Rold TL; Hoffman TJ; Smith CJ; Pietzsch HJ
Bioconjug Chem; 2007; 18(5):1651-61. PubMed ID: 17663527
[TBL] [Abstract][Full Text] [Related]
34. Breast tumor targeting with (99m)Tc-HYNIC-PR81 complex as a new biologic radiopharmaceutical.
Salouti M; Rajabi H; Babaei MH; Rasaee MJ
Nucl Med Biol; 2008 Oct; 35(7):763-8. PubMed ID: 18848661
[TBL] [Abstract][Full Text] [Related]
35. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Vahdat LT; Layman R; Yardley DA; Gradishar W; Salkeni MA; Joy AA; Garcia AA; Ward P; Khatcheressian J; Sparano J; Rodriguez G; Tang S; Gao L; Dalal RP; Kauh J; Miller K
Oncologist; 2017 Mar; 22(3):245-254. PubMed ID: 28220020
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of alternative rapid thin layer chromatography systems for quality control of technetium-99m radiopharmaceuticals.
Mang'era K; Wong D; Douglas D; Franz K; Biru T
Appl Radiat Isot; 2014 Apr; 86():57-62. PubMed ID: 24491376
[TBL] [Abstract][Full Text] [Related]
37. Preparation of (99m)Tc carbonyl DTPA-bevacizumab and its bioevaluation in a melanoma model.
Kameswaran M; Pandey U; Sarma HD; Samuel G
Ann Nucl Med; 2014 Nov; 28(9):911-6. PubMed ID: 25038907
[TBL] [Abstract][Full Text] [Related]
38. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Maione P; Sgambato A; Casaluce F; Sacco PC; Santabarbara G; Rossi A; Gridelli C
Curr Med Chem; 2017; 24(1):3-13. PubMed ID: 27855622
[TBL] [Abstract][Full Text] [Related]
39. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
40. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
